In Johnson and Johnson Revenue Breakdown There are three major business segments
- Consumer
- medical equipment
- Pharmaceutical
The overall revenue for Johnson & Johnson increased by 3% in latest Q2 – 2022 earning result compare to Q2 – 2021 same Quarter last year. Revenue came around $24.02 billion compare to $23.47 billion. Sales of drugs including Stelara, Darzalex, Imbruvica, Opsumit, and Tremfya increased during this time period, which contributed to the revenue rise. Consumer Sector has seen 6.7 % rise on sales while Medical devices and Pharmaceutical segments has seen drop in sales of 1.1% and 1.3% in Q2- 2022 compared to Q1-2021 .
Johnson and Johnson revenue breakdown from 2009 – 2021
Johnson and Johnson revenue breakdown from 2009 – 2021 , By business segment
| Year | Consumer | Pharmaceutical | Medical devices |
| 2009 | 15,803 | 22,520 | 23,574 |
| 2010 | 14,590 | 22,396 | 24,601 |
| 2011 | 14,883 | 24,368 | 25,779 |
| 2012 | 14,447 | 25,351 | 27,426 |
| 2013 | 14,697 | 28,125 | 28,490 |
| 2014 | 14,496 | 32,313 | 27,522 |
| 2015 | 13,507 | 31,430 | 25,137 |
| 2016 | 13,307 | 33,464 | 25,119 |
| 2017 | 13,602 | 36,256 | 26,592 |
| 2018 | $13,853 | $40,734 | $26,994 |
| 2019 | $13,898 | $42,198 | $25,963 |
| 2020 | $14,053 | $45,572 | $22,959 |
| 2021 | $14,635 | $52,080 | $27,060 |
Johnson & Johnson revenue By Consumer Sector 🛒 :
The Consumer division of Johnson & Johnson offers a range of items for skincare, baby care, oral care, and other personal healthcare needs. A few of the company’s well-known brands are Clean & Clear, Neutrogena, Aveeno, Benadryl, Nicorette, Listerine, Stayfree, Carefree, Band-Aid, and Neosporin. These items are used to treat allergies, coughs and colds, help people quit smoking, and relieve discomfort. These goods are distributed throughout the world by Johnson & Johnson through retail stores, wholesalers, and online shopping portals.
Johnson & Johnson’s consumer segment revenue climbed by 1.40% from $3.57 billion in Q4 2019 to $3.62 billion in Q4 2020, or $3.62 billion overall. The Consumer division generated 16.84% of the company’s overall sales in Q4 2020.
Johnson and Johnson revenue breakdown By medical equipment 💉 Sector :
The Medical Devices segment of Johnson & Johnson comprises a variety of tools utilized in surgery, interventional solutions, orthopedics, and vision fields.
- Surgery: Johnson & Johnson offers procedures for the ear, nose, and throat as well as other complex and routine surgeries.
- Interventional Solutions: The business sells medical equipment for treating hemorrhagic and ischemic strokes, as well as cardiovascular disorders.
- Orthopedics: Johnson & Johnson’s orthopedic product line includes orthopedics for the spine, knees, hips, and trauma. Depuy Synthes is the company’s leading brand in the orthopedic market.
Vision Fields: The Johnson & Johnson Vision Fields product line consists of ophthalmic items for cataract and laser eye surgery. Acuvue is the primary brand of the corporation in this market.
Doctors, nurses, ophthalmologists, and physicians use the products that the company provides to merchants and hospitals.
Johnson & Johnson’s Medical Devices sector revenue decreased from $6.63 billion in the fourth quarter of 2019 to $5.93 billion in the fourth quarter of 2020, a decline of 10.55% on an annual basis. The Medical Devices division provided 27.58% of Johnson & Johnson’s overall revenue during this time.
Johnson & Johnson revenue By Pharmaceutical Sector 💊 :
The pharmaceutical division of Johnson & Johnson concentrates on oncology, neuroscience, infectious diseases, cardiovascular and metabolism, and pulmonary hypertension. The following are some of the company’s top pharmaceutical brands:
Stelara: is a medication used to treat both children and adults with severe plaque psoriasis.
Remicade : is a drug used to treat inflammatory illnesses with an immunological component.
Adults with schizophrenia and bipolar disorder are treated with risperidone-conta.
opsumit : is used to treat pulmonary arterial hypertension.
Invokamet SR: is a medication used to treat adults with type 2 diabetes.
Johnson & Johnson’s Pharmaceutical segment revenue increased by 11.05% year over year, from $10.76 billion in the fourth quarter of 2019 to $11.95 billion in the fourth quarter of 2020. Johnson & Johnson’s overall revenue in Q4 2020 was 55.58% of the Pharmaceutical segment’s total revenue.
Johnson & Johnson Business Overview :
American multinational healthcare corporation Johnson & Johnson. James Johnson, Edward Johnson, and Robert Johnson began the business in 1886. The headquarters of Johnson & Johnson are in New Brunswick, New Jersey, in the United States. The company’s current chairman and CEO is Alex Gorsky. More than 130,000 individuals work for Johnson & Johnson across the globe. The majority of the world’s population can purchase the company’s items. The manufacturing sites of Johnson & Johnson are spread across the Americas, Europe, Africa, Asia, and the Pacific.
Novartis, Merck, Roche, Boston Scientific, Abbott, Glaxo Smith Kline, Pfizer, and Medtronic are among of the company’s fiercest rivals. Momenta Pharmaceuticals, Mitek Products, Janssen, 3-Dimensional Pharmaceuticals, Auris Health, Verb Surgical, Taris Biomedical, and numerous more businesses have been bought by Johnson & Johnson over the years. These purchases have aided the business in expanding its line of products and fending off market competition. The stock ticker symbol for Johnson & Johnson on the NYSE is “JNJ.”
You do want to book mark our chart section we post daily new charts.
